These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9053488)

  • 1. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
    McGuire W; Neugut AI; Arikian S; Doyle J; Dezii CM
    J Clin Oncol; 1997 Feb; 15(2):640-5. PubMed ID: 9053488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A; Trippoli S; Becagli P; Tendi E
    Cancer; 1996 Dec; 78(11):2366-73. PubMed ID: 8941008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacoeconomics of cancer therapies.
    Bishop JF; Macarounas-Kirchman K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
    Messori A; Trippoli S
    Anticancer Drugs; 1998 Nov; 9(10):909-16. PubMed ID: 9890702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
    Elit LM; Gafni A; Levine MN
    J Clin Oncol; 1997 Feb; 15(2):632-9. PubMed ID: 9053487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.
    Ortega A; Dranitsaris G; Sturgeon J; Sutherland H; Oza A
    Gynecol Oncol; 1997 Sep; 66(3):454-63. PubMed ID: 9299261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
    Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T; Vance RB; McGuire WP; Hoskins WJ; Brady M
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A; Cecchi M; Becagli P; Trippoli S
    Cancer; 1997 Jun; 79(11):2264-6. PubMed ID: 9179077
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials.
    Rose PG; Lappas PT
    Gynecol Oncol; 2000 Jul; 78(1):3-6. PubMed ID: 10873400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gynecologic oncology group trials in ovarian carcinoma.
    Ozols RF
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-10-S2-12. PubMed ID: 9045325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.